Greenwich LifeSciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Stafford, texas, march 13, 2024 (globe newswire) -- greenwich lifesciences, inc. (nasdaq: glsi) (the "company"), a clinical-stage biopharmaceutical company focused on its phase iii clinical trial, flamingo-01, which is evaluating glsi-100, an immunotherapy to prevent breast cancer recurrences, today announced that its board of directors has extended the lock-up of the shares owned by the company's directors, officers, and existing pre-ipo investors to june 30, 2025 which is approximately 57 months from date of the company's ipo. during this period, current officers, directors and certain shareholders will not be able to sell their shares of the company's common stock unless otherwise modified by the board of directors.

Stafford, texas, march 12, 2024 (globe newswire) -- greenwich lifesciences, inc. (nasdaq: glsi) (the "company"), a clinical-stage biopharmaceutical company focused on its phase iii clinical trial, flamingo-01, which is evaluating glsi-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in europe in collaboration with geicam in spain.

Stafford, texas, feb. 27, 2024 (globe newswire) -- greenwich lifesciences, inc. (nasdaq: glsi) (the "company"), a clinical-stage biopharmaceutical company focused on its phase iii clinical trial, flamingo-01, which is evaluating glsi-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into europe.

Stafford, texas, feb. 22, 2024 (globe newswire) -- greenwich lifesciences, inc. (nasdaq: glsi) (the "company"), a clinical-stage biopharmaceutical company focused on its phase iii clinical trial, flamingo-01, which is evaluating glsi-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into europe.

Stafford, texas, feb. 14, 2024 (globe newswire) -- greenwich lifesciences, inc. (nasdaq: glsi) (the "company"), a clinical-stage biopharmaceutical company focused on the development of glsi-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the phase iii clinical trial, flamingo-01.

Source: g0d4ather / Shutterstock.com Short squeeze stocks are still popular with speculative traders and that has us going over the top ones to keep an eye on this week! Luckily, Fintel has traders covered with its Short Squeeze Leaderboard.

Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we've got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze stocks to watch with its Short Squeeze Leaderboard.

Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Leaderboard.

Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they search for the next big breakout.

Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data.

While most people don't like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for short-term stocks to buy for a quick profit. Here, the narrative isn't necessarily about finding a great company on discount.

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Greenwich Lifesciences says through discussions with the FDA and testing of GP2 in the.

Greenwich Lifesciences (GLSI) stock is heading higher on Tuesday after the FDA lifted a hold on a Phase III clinical trial. The post Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame.

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.